Teva Pharmaceutical Industries Limited American Depositary Shares News
Elon Musk Warns Against Adderall
The billionaire influencer is not a fan of a particular pharmaceutical.
FDA Announces Shortage of This Crucial Drug
Teva and the FDA seem to have differing views on what is causing the shortage.
Teva Recalls Drug Vials, Shuts Facility Over Mold Concerns
Teva Pharmaceuticals reportedly recalls more than 2.5 million vials of drugs due to potential contamination.
Endo International Stock Jumps on $50M Opioid-Claim Accord
Endo said the settlement includes no admission of wrongdoing by Endo or its subsidiaries.
5 Top Stock Gainers for Wednesday: Tilray, Boeing and Alphabet
Tilray, Boeing, Alphabet, QuantumScape and Teva Pharmaceutical are five top stock gainers for Wednesday.
Teva Stock Climbs After Earnings Match Estimates
Teva maintains its earnings guidance for the year.
Teva Halts Search for Partners to Develop COVID-19 Vaccine
Teva Pharmaceutical reportedly stopped looking for partners to develop a COVID vaccine, saying candidates went with other companies.
Teva's Fourth-Quarter Adjusted Earnings Top Forecasts
Teva's fourth-quarter adjusted earnings top analysts' forecasts. Revenue falls from a year earlier but also beats forecasts.
Teva 3rd-Quarter Adjusted Profit Meets Estimate; Revenue Lags
Teva shares were lower after the drugmaker's adjusted earnings matched analyst expectations while revenue lagged.
Magnificent Seven: Cramer's 'Mad Money' Recap (Monday 10/19/20)
For some stocks, earnings are essential. But Jim Cramer has a 'Magnificent Seven' list of growth stocks for which it seems like every day is a buying opportunity.
Johnson & Johnson Faces New York State Fraud Action Linked to Opioid Crisis
Johnson & Johnson Faces New York State Insurance Fraud Action Linked to Opioid Crisis
Teva Is Said to Face U.S. Charge in Price-Fixing Inquiry
Teva may face a federal charge stemming from a price-fixing investigation, a media report says.
Teva Sued by U.S. Government Over Alleged Copaxone Kickbacks
The government claims that kickbacks Teva paid for its multiple sclerosis drug Copaxone led to false Medicare claims.
Berkshire Hathaway Expected to Earn $2.12 a Share
Berkshire Hathaway revenue expected to fall 4% to $61.1 billion.
State Attorneys General Sue Generic Drugmakers for Inflating Prices
Mylan, Teva, Taro and Perrigo are among those accused of price-fixing, market allocation and bid-rigging on 80 topical drugs.
New Market: Cramer's 'Mad Money' Recap (Thursday 5/28/20)
Jim Cramer says there are good reasons for this reopening rally, and support from the Fed and Treasury. But job losses are a worry.
Buffett Exits Phillips 66 and Travelers, Trims Goldman Sachs
Latest SEC filings also show Berkshire Hathaway added to PNC holdings.
Teva Soars as Generic Drugmaker Tops Earnings and Revenue Estimates
Teva reports rising demand for its respiratory drugs amid the Covid-19 pandemic.
Coronavirus Latest Updates: A Timeline of Recent Events
Here is TheStreet's latest news on the coronavirus and its worldwide and economic impact, and a timeline of events since January
Teva Donates 6 Million Tablets of Malaria Drug to Fight Coronavirus in U.S.
Teva plans to give those shipments to U.S. hospitals by March 31 and another 4 million within a month.
Teva Pharmaceutical Industries Limited American Depositary Shares News from TheStreet Pro
This Biotech Stock Is a Gift at $10
Here's the 'rinse, wash and repeat' trade strategy that continues to be profitable for me.
I've Spotted Three Biotech Bargains Amid the Melt-Up
Here are some cheap names I'm playing via covered-call orders.
Teva Makes My Anticipated Upside Breakout as Trend Strength Improves
Let's check and see how my trade is going.
My Doctor Might Prescribe Teva, but Would I Prescribe the Stock?
Let's get a technical take on the health of the pharma play.
There's Nothing Generic About Teva's Rally
The stock has been in an impressive uptrend over the past 12 months. Now, let's let the charts determine our trading strategy from here.
A Checkdown Trade on a Small-Cap Biotech Stock
This options strategy is prudent while the company navigates through an inflection point.
I Still Believe ... in the Correction
Let's check the inverse move today in which the indexes got hit and breadth held fast, also let's check the banks and the biotechs.
2 Biotech Stocks to Watch as Their Growth Stories Brighten
These small and mid-cap names have seen major news of late.
A Tight Hold on $100
The TLT is holding onto that $100 area for dear life, and here's what breaking it could mean -- and why this is so fascinating.
Teva Pharmaceutical Rallies, So Let's Adjust Our Bullish Strategy
The shares rallied nicely in December.
The Indicators Just Can't Commit
For those who thought the indicators would resolve to get it together in the new year and end this weeks' long on-and-off chop, think again. Also, let's look at new lows on the Nasdaq since August and the oversold/overbought condition.
As Bulls and Bears Cheer Market, Do They Know They're at a Chop-fest?
Let's see where we haven't gone in a month -- also let's check the buck, small caps and the intermediate-term indicators.
Teva Pharmaceutical Is Bottoming: Here's My Strategy
Let's check the charts of this generic drug maker.
This Holding Reports a Beat
Antares Pharma showed solid earnings in the fourth quarter. Here's our take.
3 Portfolio Names Report Results: Here's What We Think
Breaking down first-quarter reports from Energy Recovery, Antares Pharma and 22nd Century Group.
Teva Pharmaceutical Gets a Quantitative Upgrade to Hold
Let's review the charts and indicators.
Good News on a Healthcare Position
An update on Antares Pharma and where we stand with our price target.
This Health Care Position Had the Right Prescription in Q3
Results for Antares Pharma were driven by Xyosted, the company’s hottest product.
This Pharma Name Is Beating Our Expectations
Antares Pharma had a better quarter than expected, so let's look at the company in detail here.
Think Monday Looked Good? Think Again.
Statistically speaking, it was, how shall we say this, bad.
Breaking News
Billionaire Bill Ackman makes a bold bet on housing market
The long-time hedge fund manager thinks two stocks could soon surge higher.
Meta Platforms leaked emails reveal fierce AI rivalry
Mark Zuckerberg's AI team unveiled big plans for AI in an email chain
Best-rated 2025 SUVs under $40k according to Consumer Reports
These 10 compact and midsized sport utility vehicles earned CR’s highest marks, and they sell for wallet-friendly prices.
Bank of America reveals top technology stock pick for 2025
Here’s what could be next in the AI boom.